ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of ArriVent BioPharma (NASDAQ:AVBP) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $25.00 price objective on the stock.

A number of other analysts have also recently weighed in on AVBP. Jefferies Financial Group initiated coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $35.00 price target for the company. Citigroup initiated coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $30.00 price target for the company. Finally, The Goldman Sachs Group initiated coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $27.00 price target for the company.

ArriVent BioPharma Stock Up 1.1 %

Shares of ArriVent BioPharma stock opened at $16.52 on Tuesday. The firm has a fifty day moving average of $18.19. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $25.95.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.